High-risk MDS
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) (NCT04184505) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-11-27 |
| Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. (NCT02159040) | Novartis Pharmaceuticals | 2014-09-11 |
Track High-risk MDS automatically
Every clearance here is in the API, with alerts when new ones post.